1 |
NCT03347474 |
Recruiting |
Novel Deep Brain Stimulation in Ventral Capsule/Ventral Striatum for Methamphetamine Addiction |
- Treatment Methamphetamine Addiction
|
- Procedure: Bilateral surgical implantation of DBS system to VC/ VS
|
Interventional |
Not Applicable |
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- change in 10-point visual analog scale of carving
- change in Addiction Severity Index(ASI)
- Change in the Hamilton Anxiety Scale
- (and 7 more...)
|
6 |
All |
18 Years to 65 Years (Adult) |
NCT03347474 |
DBS Methamphetamine |
|
September 20, 2017 |
September 20, 2018 |
December 30, 2018 |
November 20, 2017 |
February 28, 2018 |
|
- Shanghai Ruijin Hospital Functional Neurosurgery
Shanghai, Shanghai, China
|
2 |
NCT03341078 |
Not yet recruiting |
Pilot Study of the Effect of Ibudilast on Neuroinflammation in Methamphetamine Users |
- Methamphetamine Dependence in Remission
|
- Drug: Ibudilast
- Drug: Placebo Oral Tablet
|
Interventional |
Phase 2 |
- Oregon Health and Science University
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- Effects of ibudilast on neuroinflammation as assessed by magnetic resonance spectroscopy (MRS)
- Effects of ibudilast on neuroinflammation as assessed by positron emission tomography (PET)
- Effects of ibudilast on brain function as assessed by magnetic resonance imaging (MRI)
- Effects of ibudilast on overall cognitive battery score.
|
28 |
All |
18 Years to 55 Years (Adult) |
NCT03341078 |
16768 |
Ibudilast |
May 2018 |
January 2020 |
January 2020 |
November 14, 2017 |
February 12, 2018 |
|
|
3 |
NCT03078075 |
Recruiting |
Accelerated Development of Additive Pharmacotherapy Treatment (ADAPT-2) for Methamphetamine Use Disorder |
- Methamphetamine Use Disorder
|
- Drug: Active Medication Combination (AMC)
- Drug: Placebo (PLB)
|
Interventional |
Phase 3 |
- University of Texas Southwestern Medical Center
- National Institute on Drug Abuse (NIDA)
- The EMMES Corporation
|
Other / NIH / Industry |
- Allocation: Randomized
- Intervention Model: Sequential Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Methamphetamine use
- Drug use other than methamphetamine
|
370 |
All |
18 Years to 65 Years (Adult) |
NCT03078075 |
CTN-0068 UG1DA020024 |
ADAPT-2 |
May 5, 2017 |
March 2019 |
March 2019 |
March 13, 2017 |
February 14, 2018 |
|
- University of California Los Angeles (UCLA) Center for Behavioral Addiction Medicine (CBAM)
Los Angeles, California, United States - Substance Use Research Unit (SURU) at the San Francisco Dept. of Public Health
San Francisco, California, United States - Hennepin County Medical Center- Berman Center for Research
Minneapolis, Minnesota, United States - (and 4 more...)
|
4 |
NCT02907853 |
Recruiting |
Contingency Management for Meth in South Africa Methamphetamine Abuse in South Africa |
|
- Behavioral: Contingency Management
|
Interventional |
Phase 1 Phase 2 |
- University of California, Los Angeles
- University of Cape Town
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Responses to Contingency Management
- fMRI Measures
- Stop Signal Task
- (and 3 more...)
|
30 |
All |
18 Years to 45 Years (Adult) |
NCT02907853 |
R21CMinSA |
|
September 2015 |
August 2018 |
August 2018 |
September 20, 2016 |
February 15, 2018 |
|
- Department of Psychiatry at Groote Schuur Hospital
Cape Town, South Africa
|
5 |
NCT03106571 |
Not yet recruiting |
Study of Pomaglumetad and Methamphetamine |
- Methamphetamine Use Disorder
|
- Drug: Pomaglumetad methionil
- Drug: Placebo
- Drug: Methamphetamine
|
Interventional |
Phase 1 |
- University of California, Los Angeles
- National Institute on Drug Abuse (NIDA)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Blood pressure
- Heart rate
- Rate-pressure product
- (and 2 more...)
|
24 |
All |
18 Years to 55 Years (Adult) |
NCT03106571 |
R01DA043238 |
POMA-MA-Ph1 |
May 2017 |
May 2019 |
December 2019 |
April 10, 2017 |
April 11, 2017 |
|
- UCLA
Santa Monica, California, United States
|
6 |
NCT03336866 |
Recruiting |
Study of Antibody for Methamphetamine Outpatient Therapy |
- Methamphetamine-dependence
- Methamphetamine Abuse
|
- Drug: Placebo
- Drug: IXT-m200
|
Interventional |
Phase 1 Phase 2 |
- InterveXion Therapeutics, LLC
- National Institute on Drug Abuse (NIDA)
|
Industry / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Change in serum methamphetamine (METH) area under the curve or Cmax resulting from METH challenge doses following single IV doses of IXT-m200
- Change in subjective effects of METH challenge doses
- Safety and tolerability of IXT-m200 followed by METH challenges
- Pharmacokinetics of IXT-m200 following single administration
|
126 |
All |
21 Years to 50 Years (Adult) |
NCT03336866 |
M200C-1801 U01DA045366 |
STAMPOUT |
May 2018 |
November 2019 |
November 2019 |
November 8, 2017 |
April 17, 2018 |
|
- PRA Health Sciences
Salt Lake City, Utah, United States
|
7 |
NCT01967381 |
Recruiting |
Targeting GABA and Opioid Systems for a Pharmacotherapy for Methamphetamine Abuse |
- Methamphetamine Abuse
- Methamphetamine Dependence
|
- Drug: Methamphetamine (Desoxyn®)
|
Interventional |
Early Phase 1 |
- University of Kentucky
- National Institute on Drug Abuse (NIDA)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: Triple (Participant, Care Provider, Outcomes Assessor)
- Primary Purpose: Basic Science
|
- Reinforcing Effects
- Subjective Effects
- Physiological and Side Effects
|
28 |
All |
18 Years to 55 Years (Adult) |
NCT01967381 |
R01DA033394 |
|
October 2013 |
September 2018 |
September 2018 |
October 22, 2013 |
March 1, 2018 |
|
- University of Kentucky Medical Center
Lexington, Kentucky, United States
|
8 |
NCT03059563 |
Not yet recruiting |
Dopamine D2/D3 Receptor Upregulation by Varenicline in Methamphetamine Users |
- Dopamine D2/3 Receptor Availability
- Cognitive Function
- Methamphetamine Abuse
|
- Drug: Varenicline
- Other: Placebo
|
Interventional |
Phase 1 |
- University of California, Los Angeles
- Tarzana Treatment Center
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Basic Science
|
- Dopamine D2-type receptor availability
- Sustained attention
- Working memory
- (and 8 more...)
|
36 |
All |
18 Years to 50 Years (Adult) |
NCT03059563 |
17-000445 |
|
April 2017 |
April 2019 |
April 2019 |
February 23, 2017 |
February 23, 2017 |
|
|
9 |
NCT03470480 |
Recruiting |
rTMS for Craving in Methamphetamine Use Disorder |
- Methamphetamine Abuse
- Substance Use Disorders
- Stimulant Dependence
- (and 3 more...)
|
- Device: Real Repetitive transcranial magnetic stimulation
- Device: Sham Repetitive transcranial magnetic stimulation
- Behavioral: Methamphetamine visual cues
- Behavioral: Neutral visual cues
|
Interventional |
Not Applicable |
- Oregon Health and Science University
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Effect of rTMS directed at left DLPFC on craving for methamphetamine as assessed by the Severity of Dependence Scale.
- Effect of rTMS directed at left DLPFC on craving for methamphetamine as assessed by a Visual Analog Scale (VAS).
- Effect of rTMS directed at left DLPFC on craving for methamphetamine as assessed by the Stimulant Craving Questionnaire (STCQ).
- (and 2 more...)
|
20 |
All |
18 Years to 65 Years (Adult) |
NCT03470480 |
GPSYC0236A |
|
February 7, 2018 |
September 1, 2018 |
September 1, 2018 |
March 20, 2018 |
March 20, 2018 |
|
- Veterans Affairs Portland Health Care System
Portland, Oregon, United States
|
10 |
NCT02948868 |
Recruiting |
Combating Craving With Contingency Management: Neuroplasticity and Methamphetamine Abuse in South Africa |
|
- Behavioral: Contingency Management
|
Interventional |
Not Applicable |
- University of Cape Town
- University of California, Los Angeles
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Study on working memory in methamphetamine to assess a change from baseline to follow up after contingency management as assessed by fMRI
- Methamphetamine users assessed for risk taking measures to assess a change from baseline to follow up after contingency management assessed by SPSS
- Participants assessed for a variant of risk taking analysed by SPSS
- (and 4 more...)
|
30 |
All |
18 Years to 45 Years (Adult) |
NCT02948868 |
R21DA040492 |
CM |
January 2016 |
December 2017 |
December 2017 |
October 31, 2016 |
November 4, 2016 |
|
- University of Cape Town
Cape Town, Western Cape, South Africa
|
11 |
NCT03382379 |
Recruiting |
Transcranial Direct Current Stimulation to Modulate Top-Down Regulation for Drug Craving in Methamphetamine Use Disorder |
- Amphetamine Use Disorders
|
- Device: Active transcranial Direct Current Stimulation (tDCS)
- Device: Sham transcranial Direct Current Stimulation (tDCS)
|
Interventional |
Phase 1 Phase 2 |
- Laureate Institute for Brain Research, Inc.
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Basic Science
|
- Change in Drug Cue Reactivity BOLD Signal in fMRI from before to after Intervention
- Change in Drug Cue Reactivity Self-Report from before to after Intervention
- Change in Cortical-Subcortical Connectivity in Resting State fMRI from before to after Intervention
- (and 5 more...)
|
60 |
Male |
18 Years to 60 Years (Adult) |
NCT03382379 |
2017-005-00 |
NeuroMethDC |
November 30, 2017 |
September 10, 2019 |
September 10, 2020 |
December 22, 2017 |
December 22, 2017 |
|
- Laureate Institute for Brain Research
Tulsa, Oklahoma, United States
|
12 |
NCT02192931 |
Recruiting |
A Randomized Double-Blind Controlled Trial of Creatine in Female Methamphetamine Users |
- Depression
- Dual Diagnosis
- Drug Addiction
|
- Drug: Creatine monohydrate
|
Interventional |
Phase 4 |
- Perry Renshaw
- University of Utah
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- Hamilton Depression Rating Scale (HAMD) scores
- Beck Anxiety Inventory (BAI) scores
|
147 |
Female |
18 Years to 55 Years (Adult) |
NCT02192931 |
73034 |
|
September 2014 |
October 2021 |
October 2021 |
July 17, 2014 |
August 24, 2017 |
|
- University of Utah
Salt Lake City, Utah, United States
|
13 |
NCT03226223 |
Recruiting |
Pharmacogenetics of Naltrexone for Stimulant Abuse |
- Substance Use Disorders
- Methamphetamine Abuse
|
- Drug: Intranasal Methamphetamine
|
Interventional |
Phase 2 |
- New York State Psychiatric Institute
|
Other |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: Single (Participant)
- Primary Purpose: Basic Science
|
- Percentage of methamphetamine choices.
- Positive subjective effects of methamphetamine.
|
70 |
All |
21 Years to 50 Years (Adult) |
NCT03226223 |
#7347 |
|
September 15, 2016 |
July 30, 2019 |
July 30, 2020 |
July 21, 2017 |
July 21, 2017 |
|
- New York State Psychiatric Institute
New York, New York, United States
|
14 |
NCT02881177 |
Recruiting |
Oxytocin HIV Meth Study |
- Amphetamine Use Disorders
|
- Drug: Oxytocin
- Drug: Placebo
|
Interventional |
Phase 1 |
- University of California, San Francisco
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Other
|
- Tolerability
- Feasibility
- Exploratory Effectiveness
|
50 |
Male |
18 Years to 65 Years (Adult) |
NCT02881177 |
16-20360 |
OHM |
January 2017 |
July 2018 |
July 2018 |
August 26, 2016 |
December 8, 2017 |
|
- University of California, San Francisco
San Francisco, California, United States
|
15 |
NCT03175159 |
Recruiting |
Integrated BA and HIV RR Counseling for MSM With Stimulant Abuse |
- Stimulant Abuse
- HIV Prevention
- Substance Abuse
|
- Behavioral: Time & Intensity Matched Control
- Behavioral: IMPACT
- Behavioral: Standard of Care
|
Interventional |
Not Applicable |
- Brown University
- University of Miami
- The Fenway Institute
|
Other |
- Allocation: Randomized
- Intervention Model: Factorial Assignment
- Masking: Single (Outcomes Assessor)
- Primary Purpose: Prevention
|
- Reduction in Condomless Anal Sex Acts (CAS) over study follow-up
- Reduction in the number of stimulant use episodes over study follow-up
|
286 |
Male |
18 Years and older (Adult, Senior) |
NCT03175159 |
1R01DA042805-01A1 |
|
March 1, 2018 |
May 1, 2021 |
May 1, 2022 |
June 5, 2017 |
April 4, 2018 |
|
- University of Miami
Miami, Florida, United States - Fenway Community Health Center
Boston, Massachusetts, United States
|
16 |
NCT03444974 |
Not yet recruiting |
Addiction Disorders in Adolescence- Underlying Pathomechanisms and Treatment Evaluation |
- Drug Abuse and Dependency
- Adolescent Behavior
|
- Other: adapted treatment according to the Matrix therapy
|
Interventional |
Not Applicable |
- Technische Universität Dresden
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Sociodemographic data- Highest Education
- Sociodemographic data- Gender
- Sociodemographic data- Migration background
- (and 20 more...)
|
450 |
All |
12 Years to 18 Years (Child, Adult) |
NCT03444974 |
Matrix_UKD |
|
February 2018 |
February 2020 |
February 2021 |
February 26, 2018 |
February 27, 2018 |
|
- Youth Drug Outpatient Department of the C.G.C. University Hospital Dresden
Dresden, Saxony, Germany
|